Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sorafenib/MG 010 - Metagone Biotech

Next Previous
Drug Profile

Sorafenib/MG 010 - Metagone Biotech

Alternative Names: MG 010/Sorafenib; MG D 1609

Latest Information Update: 11 Dec 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Metagone Biotech
  • Class Amides; Antineoplastics; Benzenesulfonates; Chlorobenzenes; Pyridines; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Death-associated protein kinase inhibitors; Fms-like tyrosine kinase 3 inhibitors; Mitogen-activated protein kinase inhibitors; Mitogen-activated protein kinase kinase inhibitors; Platelet-derived growth factor beta receptor antagonists; Proto oncogene protein c raf inhibitors; Proto-oncogene protein b-raf inhibitors; Proto-oncogene protein c-kit inhibitors; Proto-oncogene protein c-ret inhibitors; Raf kinase inhibitors; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists; Vascular endothelial growth factor receptor-3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours
  • No development reported Gastric cancer

Most Recent Events

  • 06 Dec 2023 Metagone biotech plans a phase III trial for Cancer in the Q4 of 2023 (Metagone biotech pipeline, December 2023)
  • 28 Oct 2022 No recent reports of development identified for preclinical development in Gastric-cancer in Taiwan
  • 31 Jan 2022 Metagone biotech plans a phase II trial for Lung cancer, Colorectal cancer, liver cancer and Kidney cancer in the Q2 of 2019 (Metagone biotech pipeline, January 2022)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top